Nuveen
IMVT icon

Nuveen’s Immunovant IMVT Stock Holding History

Nuveen’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2M Buy
602,046
+360,851
+150% +$11M 0.01% 1170
2026
Q1 		$5.99M Buy
241,195
+14,706
+6% +$381K ﹤0.01% 1809
2025
Q4 		$5.76M Buy
226,489
+1,449
+0.6% +$32.3K ﹤0.01% 1845
2025
Q3 		$3.63M Sell
225,040
-59
-0% -$955 ﹤0.01% 2063
2025
Q2 		$3.6M Sell
225,099
-8,886
-4% -$134K ﹤0.01% 2040
2025
Q1 		$4M Sell
233,985
-681,166
-74% -$14.2M ﹤0.01% 2030
2024
Q4 		$22.7M Sell
915,151
-189,759
-17% -$5.38M 0.01% 1111
2024
Q3 		$31.5M Sell
1,104,910
-39,939
-3% -$1.18M 0.01% 901
2024
Q2 		$30.2M Buy
1,144,849
+40,571
+4% +$1.15M 0.01% 870
2024
Q1 		$35.7M Sell
1,104,278
-122,988
-10% -$4.49M 0.01% 811
2023
Q4 		$51.7M Buy
1,227,266
+199,050
+19% +$7.32M 0.02% 591
2023
Q3 		$39.5M Buy
1,028,216
+240,965
+31% +$5.45M 0.01% 660
2023
Q2 		$14.9M Buy
787,251
+264,855
+51% +$4.94M 0.01% 1263
2023
Q1 		$8.1M Buy
522,396
+198,478
+61% +$3.44M ﹤0.01% 1618
2022
Q4 		$5.75M Buy
323,918
+145,490
+82% +$1.83M ﹤0.01% 1831
2022
Q3 		$995K Sell
178,428
-3,089
-2% -$15.1K ﹤0.01% 2754
2022
Q2 		$708K Sell
181,517
-41,568
-19% -$180K ﹤0.01% 2927
2022
Q1 		$1.32M Sell
223,085
-148,865
-40% -$927K ﹤0.01% 2691
2021
Q4 		$3.17M Buy
371,950
+12,643
+4% +$104K ﹤0.01% 2346
2021
Q3 		$3.12M Sell
359,307
-38,075
-10% -$343K ﹤0.01% 2454
2021
Q2 		$4.2M Buy
397,382
+31,199
+9% +$436K ﹤0.01% 2333
2021
Q1 		$5.87M Sell
366,183
-59,483
-14% -$1.57M ﹤0.01% 2097
2020
Q4 		$19.7M Buy
425,666
+68,686
+19% +$3.18M 0.01% 1282
2020
Q3 		$12.6M Buy
356,980
+167,829
+89% +$5.05M ﹤0.01% 1371
2020
Q2 		$4.61M Buy
+189,151
New +$4.05M ﹤0.01% 1938

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Nuveen's IMVT Position: Q2 2026 in Review

Nuveen increased its Immunovant (IMVT) stake by 150% in Q2 2026, buying an estimated $11M and bringing the position to 602,046 shares worth $23.2M. The position accounts for 0.01% of the portfolio, ranked #1170.

Nuveen first reported a position in IMVT in Q2 2020 and has held it in 25 quarters since. The position peaked at $51.7M in Q4 2023. 227 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Nuveen held 602,046 shares of Immunovant worth $23.2M as of Q2 2026.
  • Nuveen bought 360,851 Immunovant shares in Q2 2026, an estimated $11M.
  • Immunovant made up 0.01% of Nuveen's portfolio in Q2 2026, its #1170 holding.
  • Nuveen first reported a position in Immunovant in Q2 2020 and has held it in 25 quarters since.
  • Nuveen's Immunovant position peaked at $51.7M in Q4 2023.
  • 227 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.